- SMYD2 INHIBITORS
-
The present disclosure generally relates to compounds having cellular anti-proliferative activities, and more particularly relates to compounds which inhibit the activity of human SMYD2, a SET and MYND domain-containing protein lysine methyltransferase.
- -
-
Paragraph 0118
(2016/02/20)
-
- Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2
-
A lack of useful small molecule tools has precluded thorough interrogation of the biological function of SMYD2, a lysine methyltransferase with known tumor-suppressor substrates. Systematic exploration of the structure-activity relationships of a previous
- Sweis, Ramzi F.,Wang, Zhi,Algire, Mikkel,Arrowsmith, Cheryl H.,Brown, Peter J.,Chiang, Gary G.,Guo, Jun,Jakob, Clarissa G.,Kennedy, Steven,Li, Fengling,Maag, David,Shaw, Bailin,Soni, Nirupama B.,Vedadi, Masoud,Pappano, William N.
-
supporting information
p. 695 - 700
(2015/06/30)
-
- NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA-2 RECEPTORS
-
The present invention relates to named compounds of the formula (I) having both M3 receptor antagonist and β2 agonist activity; compositions comprising such compounds; the use of such compounds in therapy (such as respiratory tract disorders); and a metho
- -
-
Page/Page column 50-51
(2010/04/03)
-
- BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS
-
The present invention provides a compound of formula (I), wherein W, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
- -
-
Page/Page column 33-34
(2010/01/12)
-
- AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES
-
The present invention provides compounds of formula (I), wherein k, Ar, R2, R3, R4, R5, R4', R5', R6, R7, A, D, m and E are as defined in the specification, processes
- -
-
Page/Page column 86
(2008/12/06)
-